Where Viridian Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 Wall Street analysts have provided ratings on Viridian Therapeutics (NASDAQ:VRDN), with 2 being bullish and 5 somewhat bullish. The average price target is $37.29, which is significantly higher than the current price of $14.3, suggesting a substantial upside. However, this target is a 13.28% decrease from the previous target of $43.00.
November 14, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics has received positive ratings from analysts, with an average price target that suggests a significant upside from the current stock price.
The unanimous positive ratings from analysts and a high average price target compared to the current price indicate a strong bullish sentiment, which could lead to a short-term increase in the stock price. However, the decrease in the average price target from $43.00 to $37.29 may temper some of the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100